283 related articles for article (PubMed ID: 23178953)
1. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
Qi WX; He AN; Shen Z; Yao Y
Br J Clin Pharmacol; 2013 Sep; 76(3):348-57. PubMed ID: 23617405
[TBL] [Abstract][Full Text] [Related]
4. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
5. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
Balagula Y; Wu S; Su X; Feldman DR; Lacouture ME
Invest New Drugs; 2012 Aug; 30(4):1773-81. PubMed ID: 21394443
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
7. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Kapadia S; Hapani S; Choueiri TK; Wu S
Acta Oncol; 2013 Aug; 52(6):1202-12. PubMed ID: 23594201
[TBL] [Abstract][Full Text] [Related]
8. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib: Clinical development of a potent anti-angiogenic drug.
Schutz FA; Choueiri TK; Sternberg CN
Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.
Zhang X; Shao Y; Wang K
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1109-15. PubMed ID: 27181268
[TBL] [Abstract][Full Text] [Related]
15. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
16. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
Schutz FA; Jardim DL; Je Y; Choueiri TK
Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
18. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
Fischer A; Wu S; Ho AL; Lacouture ME
Invest New Drugs; 2013 Jun; 31(3):787-97. PubMed ID: 23345001
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
Sivendran S; Liu Z; Portas LJ; Yu M; Hahn N; Sonpavde G; Oh WK; Galsky MD
Cancer Treat Rev; 2012 Nov; 38(7):919-25. PubMed ID: 22651902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
